Patents Assigned to SELVITA S.A.
-
Patent number: 10577365Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.Type: GrantFiled: December 20, 2017Date of Patent: March 3, 2020Assignees: Felicitex Therapeutics, Inc., Selvita S.A.Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova
-
Patent number: 10174013Abstract: The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.Type: GrantFiled: June 10, 2016Date of Patent: January 8, 2019Assignee: SELVITA S.A.Inventors: Wojciech Czardybon, Krzysztof Brzózka, Michal Galezowski, Renata Windak, Mariusz Milik, Magdalena Zawadzka, Pawel Guzik, Ewelina Wincza, Marta Prokop, Katarzyna Wiklik, Aleksandra Sabiniarz, Wieslaw Marek Cholody, Raymond Horvath, Tomasz Rzymski
-
Publication number: 20180305331Abstract: Disclosed in the present application is a compound of formula (I) as defined herein as well as a pharmaceutical composition comprising said compound. Further disclosed in the present application is the use of such pharmaceutical compositions for treating diseases, namely inter alia for use in the treatment of cancer, metabolic, inflammatory, autoimmune and viral diseases. The compounds disclosed herein are inhibitors of MNK1 and/or MNK2 kinases.Type: ApplicationFiled: October 20, 2016Publication date: October 25, 2018Applicant: SELVITA S.A.Inventors: Tomasz RZYMSKI, Mariusz MILIK, Krzysztof BRZOZKA, Charles-Henry FABRITIUS, Katarzyna KUCWAJ-BRYSZ, Urszula KULESZA, Ewelina WINCZA, Agnieszka DREAS, Michal GALEZOWSKI
-
Publication number: 20180265467Abstract: The present invention relates to pyrazolidine derivatives and related compounds, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of such compounds and pharmaceutical compositions for the prophylaxis and treatment of medical conditions that can be affected by inhibiting lactate dehydrogenase (LDH), in particular LDHA and/or LDHB.Type: ApplicationFiled: September 29, 2016Publication date: September 20, 2018Applicant: SELVITA S.A.Inventors: Michal GALEZOWSKI, Andrzej GONDELA, Oleksandr LEVENETS, Joanna FOGT, Lukasz DUDEK, Alicja OBARA, Jakub WOYCIECHOWSKI, Marta SOWINSKA, Marcin KROL, Artur BIELA, Tomasz RSYMSKI
-
Publication number: 20180179199Abstract: The present invention relates to the compound of formula (I) and salts, stereoisomers, tautomers or N-oxides thereof. The present invention is further concerned with the use of such a compound or salt, stereoisomer, tautomer or N-oxide thereof as medicament and a pharmaceutical composition comprising said compound.Type: ApplicationFiled: December 20, 2017Publication date: June 28, 2018Applicants: Felicitex Therapeutics, Inc., Selvita S.A.Inventors: Agnieszka Dreas, Charles-Henry Fabritius, Andrzej Dzienia, Anna Buda, Michal Galezowski, Georgiy Kachkovskyi, Urszula Kulesza, Katarzyna Kucwaj-Brysz, Agnieszka Szamborska-Gbur, Wojciech Czardybon, Maria Vilenchik, Michael Frid, Alexandra Kuznetsova
-
Publication number: 20180118718Abstract: The present invention relates to substituted quinoxaline derivatives. These compounds are useful for the prevention and/or treatment of several medical conditions including hyperproliferative disorders and diseases.Type: ApplicationFiled: May 12, 2016Publication date: May 3, 2018Applicant: Selvita S.A.Inventors: Charles-Henry Robert Yves Fabritius, Mateusz Oktawian Nowak, Katarzyna Anna Wiklik, Aleksandra Barbara Sabiniarz, Marcin Dominik Bien, Anna Malgorzata Buda, Pawel Szczepan Guzik, Arkadiusz Kacper Bialas, Henryk Edward Pawlik, Nicolas Felix Pierre Boutard
-
Patent number: 9388192Abstract: The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine/threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.Type: GrantFiled: December 20, 2013Date of Patent: July 12, 2016Assignee: Selvita S.A.Inventors: Wojciech Czardybon, Krzysztof Brzózka, Michal Galezowski, Renata Windak, Mariusz Milik, Magdalena Zawadzka, Pawel Guzik, Ewelina Wincza, Marta Prokop, Katarzyna Wiklik, Aleksandra Sabiniarz, Wieslaw Marek Cholody, Raymond Horvath, Tomasz Rzymski
-
Patent number: 8604217Abstract: A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine and tyrosine kinases and a serine/threonine and tyrosine kinases modulating agent. Novel small-molecule compounds with kinase inhibitory activity, having superior properties as pharmaceutical agents, production method thereof and uses thereof. In particular, new derivatives of tetrahalogenated benzimidazole with serine/threonine and tyrosine kinases inhibitory properties, preferably selected from the group of PIM, HIPK, DYRK, CLK, CDK, FLT, PKG, Haspin, MER, TAO, MNK, TRK kinases which exhibit superior pharmacological actions, and can be useful for the treatment of disease conditions, especially cancers depending on serine/threonine and tyrosine kinases, such as but not limited to leukemias and solid tumors.Type: GrantFiled: December 28, 2011Date of Patent: December 10, 2013Assignee: Selvita S.A.Inventors: Krzysztof Brzózka, Wojciech Czardybon, Aleksandra Sabiniarz, Mariusz Millik, Renata Windak, Adrian Zarebski, Nicolas Beuzen
-
Publication number: 20120184535Abstract: A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine and tyrosine kinases and a serine/threonine and tyrosine kinases modulating agent. Novel small-molecule compounds with kinase inhibitory activity, having superior properties as pharmaceutical agents, production method thereof and uses thereof. In particular, new derivatives of tetrahalogenated benzimidazole with serine/threonine and tyrosine kinases inhibitory properties, preferably selected from the group of PIM, HIPK, DYRK, CLK, CDK, FLT, PKG, Haspin, MER, TAO, MNK, TRK kinases which exhibit superior pharmacological actions, and can be useful for the treatment of disease conditions, especially cancers depending on serine/threonine and tyrosine kinases, such as but not limited to leukemias and solid tumors.Type: ApplicationFiled: December 28, 2011Publication date: July 19, 2012Applicant: SELVITA S.A.Inventors: Krzysztof BRZÓZKA, Wojciech CZARDYBON, Aleksandra SABINIARZ, Mariusz MILLIK, Renata WINDAK, Adrian ZAREBSKI, Nicolas BEUZEN
-
Publication number: 20110230481Abstract: A derivative of tetrabromobenzimidazole, a process for the preparation thereof, a pharmaceutical composition, a method for using the same, a method for modulating or regulating serine/threonine kinases, and a serine/threonine kinases modulating agent. The invention relates to novel small-molecule compounds with kinase inhibitory activity, having superior properties as pharmaceutical agents, production method thereof and uses thereof. In particular, this invention relates to new derivatives of tetrabromobenzimidazole with Pim kinases inhibitory properties, which exhibits superior pharmacological actions, and can be useful for the treatment of disease conditions, especially cancers depending on Pim kinases, such as leukemias and prostate cancer.Type: ApplicationFiled: November 12, 2009Publication date: September 22, 2011Applicant: SELVITA S.A.Inventors: Krzysztof Brzozka, Wojciech Czardybon, Adrian Zarebski, Nicolas Beuzen